biosyn Arzneimittel GmbH is involved in the pharmaceutical and biotech sectors, specializing in trace elements, particularly high-dose selenium injections, and operates unique GMP-active ingredient manufacturing plants.

biosyn Arzneimittel GmbH

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

MERCK Kommanditgesellschaft auf Aktien

Aenova Group is a contract manufacturer for the pharmaceutical and healthcare industry, self-described as a worldwide leader.

Aenova Group

AET Labs designs and supports technical labs for education, specializing in STEM lab equipment and solutions for schools.

AET Labs

biosyn Arzneimittel GmbH is a pharmaceutical and biotech company specializing in trace elements, particularly in high-dose selenium injections, and operates two unique GMP-based active ingredient manufacturing facilities.

biosyn Arzneimittel GmbH | 621 followers on LinkedIn. biosyn Arzneimittel GmbH is a pharmaceutical company promoting immune health in Germany&#39;s Pharmaland | We are research. We are biosyn, a health-driven biotech and pharmaceutical company.

The promotion of a healthy immune system is the elemental philosophy behind every product we develop.

Metric
Company Name	biosyn Arzneimittel GmbH	MERCK Kommanditgesellschaft auf Aktien	Aenova Group	AET Labs
Symbol		MRK
MSH ID	DE:BIOSYN	COM:MERCKGROUP	COM:AENOVA-GROUP	COM:AETLABS
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Educational Services
Industry	Pharmaceuticals	Drug Manufacturers - Specialty & Generic	Pharmaceuticals	Educational Equipment and Services
Country	DE	DE	DE	US
Stage
Employee Count		62.34K
Website	biosyn.de	merckgroup.com	aenova-group.com	aetlabs.com
LinkedIn	biosyn-arzneimittel-gmbh			aet-labs
Founders

Metric
Market Cap		68.68B
Enterprise Value
Monthly Web Traffic	1.46K	1.20M
Web Traffic Growth	0.82	0.02
Valuation
Raised Capital		2.77M

Metric
Revenue		22.17B
Revenue (LTM)
Revenue (NTM)
Gross Profit		12.33B
EBITDA		6.15B
Operating Income		4.27B
Net Income		2.98B
EPS		6.87
Diluted EPS		6.87
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.59
Operating Profit Margin		0.19
EBITDA Margin		0.28
Net Profit Margin		0.13
Return on Equity		0.10
Return on Assets		0.06
Return on Capital Employed		0.10

BIOS

DE:BIOSYN

biosyn Arzneimittel GmbH

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		22.33
P/B Ratio		2.29
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.64
EV Multiple		11.50

Metric
Days Sales Outstanding		82.97
Days Payables Outstanding		95.71
Days Inventory Outstanding		197.34
Operating Cycle		282.62
Cash Conversion Cycle		193.24
Asset Turnover		0.43

Metric
Operating Cash Flow		4.00B
Free Cash Flow		-774.22M
Cash Flow to Debt		0.41
Operating Cash Flow/Sales		0.20
Free Cash Flow Yield		0.03

Metric
Cash & Equivalents		2.09B
Accounts Receivable		-8.45M
Inventory		4.90B
Goodwill		18.85B
Debt to Capitalization		0.26
Debt to Assets		0.22
Current Ratio		1.56
Quick Ratio		0.84

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.12
SG&A to Revenue		0.06